vs

Side-by-side financial comparison of Health Catalyst, Inc. (HCAT) and HERITAGE FINANCIAL CORP (HFWA). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $66.3M, roughly 1.1× HERITAGE FINANCIAL CORP). HERITAGE FINANCIAL CORP runs the higher net margin — 33.5% vs -121.9%, a 155.4% gap on every dollar of revenue. On growth, HERITAGE FINANCIAL CORP posted the faster year-over-year revenue change (16.3% vs -6.2%). HERITAGE FINANCIAL CORP produced more free cash flow last quarter ($85.7M vs $9.6M). Over the past eight quarters, HERITAGE FINANCIAL CORP's revenue compounded faster (16.8% CAGR vs -0.0%).

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

Heritage Financial Corp (WA) is a U.S. regional financial holding company headquartered in Washington state. It provides comprehensive commercial and consumer banking services, including deposit products, small business loans, residential mortgages, personal lending and wealth management solutions, primarily serving local communities across the Pacific Northwest, with core customer segments covering small-to-medium enterprises and retail clients.

HCAT vs HFWA — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.1× larger
HCAT
$74.7M
$66.3M
HFWA
Growing faster (revenue YoY)
HFWA
HFWA
+22.5% gap
HFWA
16.3%
-6.2%
HCAT
Higher net margin
HFWA
HFWA
155.4% more per $
HFWA
33.5%
-121.9%
HCAT
More free cash flow
HFWA
HFWA
$76.0M more FCF
HFWA
$85.7M
$9.6M
HCAT
Faster 2-yr revenue CAGR
HFWA
HFWA
Annualised
HFWA
16.8%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HCAT
HCAT
HFWA
HFWA
Revenue
$74.7M
$66.3M
Net Profit
$-91.0M
$22.2M
Gross Margin
Operating Margin
-115.3%
38.7%
Net Margin
-121.9%
33.5%
Revenue YoY
-6.2%
16.3%
Net Profit YoY
-340.3%
86.4%
EPS (diluted)
$-1.29
$0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HCAT
HCAT
HFWA
HFWA
Q4 25
$74.7M
$66.3M
Q3 25
$76.3M
$65.7M
Q2 25
$80.7M
$56.5M
Q1 25
$79.4M
$57.6M
Q4 24
$79.6M
$57.1M
Q3 24
$76.4M
$54.8M
Q2 24
$75.9M
$56.4M
Q1 24
$74.7M
$48.6M
Net Profit
HCAT
HCAT
HFWA
HFWA
Q4 25
$-91.0M
$22.2M
Q3 25
$-22.2M
$19.2M
Q2 25
$-41.0M
$12.2M
Q1 25
$-23.7M
$13.9M
Q4 24
$-20.7M
$11.9M
Q3 24
$-14.7M
$11.4M
Q2 24
$-13.5M
$14.2M
Q1 24
$-20.6M
$5.7M
Gross Margin
HCAT
HCAT
HFWA
HFWA
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
HCAT
HCAT
HFWA
HFWA
Q4 25
-115.3%
38.7%
Q3 25
-22.9%
34.0%
Q2 25
-46.0%
25.6%
Q1 25
-25.4%
28.1%
Q4 24
-22.0%
28.6%
Q3 24
-17.9%
23.8%
Q2 24
-20.8%
28.4%
Q1 24
-30.5%
14.1%
Net Margin
HCAT
HCAT
HFWA
HFWA
Q4 25
-121.9%
33.5%
Q3 25
-29.1%
29.2%
Q2 25
-50.8%
21.6%
Q1 25
-29.9%
24.2%
Q4 24
-26.0%
20.9%
Q3 24
-19.3%
20.8%
Q2 24
-17.8%
25.1%
Q1 24
-27.6%
11.8%
EPS (diluted)
HCAT
HCAT
HFWA
HFWA
Q4 25
$-1.29
$0.65
Q3 25
$-0.32
$0.55
Q2 25
$-0.59
$0.36
Q1 25
$-0.35
$0.40
Q4 24
$-0.33
$0.34
Q3 24
$-0.24
$0.33
Q2 24
$-0.23
$0.41
Q1 24
$-0.35
$0.16

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HCAT
HCAT
HFWA
HFWA
Cash + ST InvestmentsLiquidity on hand
$95.7M
$233.1M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$245.8M
$921.5M
Total Assets
$502.6M
$7.0B
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HCAT
HCAT
HFWA
HFWA
Q4 25
$95.7M
$233.1M
Q3 25
$91.5M
$245.5M
Q2 25
$97.3M
$254.1M
Q1 25
$342.0M
$248.7M
Q4 24
$392.0M
$117.1M
Q3 24
$387.3M
$175.6M
Q2 24
$308.3M
$113.8M
Q1 24
$327.8M
$189.6M
Total Debt
HCAT
HCAT
HFWA
HFWA
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
HCAT
HCAT
HFWA
HFWA
Q4 25
$245.8M
$921.5M
Q3 25
$331.9M
$904.1M
Q2 25
$347.5M
$888.2M
Q1 25
$376.8M
$881.5M
Q4 24
$365.2M
$863.5M
Q3 24
$355.0M
$874.5M
Q2 24
$357.0M
$850.5M
Q1 24
$357.2M
$847.6M
Total Assets
HCAT
HCAT
HFWA
HFWA
Q4 25
$502.6M
$7.0B
Q3 25
$587.1M
$7.0B
Q2 25
$616.2M
$7.1B
Q1 25
$891.5M
$7.1B
Q4 24
$858.9M
$7.1B
Q3 24
$813.0M
$7.2B
Q2 24
$691.7M
$7.1B
Q1 24
$695.1M
$7.1B
Debt / Equity
HCAT
HCAT
HFWA
HFWA
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HCAT
HCAT
HFWA
HFWA
Operating Cash FlowLast quarter
$9.9M
$94.8M
Free Cash FlowOCF − Capex
$9.6M
$85.7M
FCF MarginFCF / Revenue
12.9%
129.1%
Capex IntensityCapex / Revenue
0.4%
13.8%
Cash ConversionOCF / Net Profit
4.26×
TTM Free Cash FlowTrailing 4 quarters
$-697.0K
$149.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HCAT
HCAT
HFWA
HFWA
Q4 25
$9.9M
$94.8M
Q3 25
$-464.0K
$25.1M
Q2 25
$-9.0M
$22.5M
Q1 25
$280.0K
$19.3M
Q4 24
$-3.5M
$64.5M
Q3 24
$6.2M
$24.2M
Q2 24
$1.6M
$6.8M
Q1 24
$10.3M
$12.9M
Free Cash Flow
HCAT
HCAT
HFWA
HFWA
Q4 25
$9.6M
$85.7M
Q3 25
$-719.0K
$24.4M
Q2 25
$-9.2M
$20.9M
Q1 25
$-390.0K
$18.1M
Q4 24
$-3.9M
$61.0M
Q3 24
$5.5M
$23.2M
Q2 24
$1.3M
$6.0M
Q1 24
$10.1M
$12.0M
FCF Margin
HCAT
HCAT
HFWA
HFWA
Q4 25
12.9%
129.1%
Q3 25
-0.9%
37.1%
Q2 25
-11.4%
37.0%
Q1 25
-0.5%
31.4%
Q4 24
-4.9%
107.0%
Q3 24
7.2%
42.4%
Q2 24
1.7%
10.6%
Q1 24
13.5%
24.7%
Capex Intensity
HCAT
HCAT
HFWA
HFWA
Q4 25
0.4%
13.8%
Q3 25
0.3%
1.0%
Q2 25
0.3%
2.8%
Q1 25
0.8%
2.0%
Q4 24
0.5%
6.1%
Q3 24
0.9%
1.7%
Q2 24
0.4%
1.5%
Q1 24
0.3%
1.8%
Cash Conversion
HCAT
HCAT
HFWA
HFWA
Q4 25
4.26×
Q3 25
1.31×
Q2 25
1.84×
Q1 25
1.38×
Q4 24
5.41×
Q3 24
2.12×
Q2 24
0.48×
Q1 24
2.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

HFWA
HFWA

Segment breakdown not available.

Related Comparisons